Ryan Smith - Cryomass Technologies Chief Meds
| CRYM Stock | USD 0.05 0.0009 2.01% |
Insider
Ryan Smith is Chief Meds of Cryomass Technologies
| Phone | 303 416 7208 |
| Web | https://cryomass.com |
Ryan Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ryan Smith against Cryomass Technologies otc stock is an integral part of due diligence when investing in Cryomass Technologies. Ryan Smith insider activity provides valuable insight into whether Cryomass Technologies is net buyers or sellers over its current business cycle. Note, Cryomass Technologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cryomass Technologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ryan Smith few days ago Disposition of 412099 shares by Ryan Smith of Elkhorn at 17.8955 subject to Rule 16b-3 | ||
Ryan Smith six days ago Acquisition by Ryan Smith of 500 shares of US Energy at 1.67 subject to Rule 16b-3 | ||
Ryan Smith over a week ago Acquisition by Ryan Smith of 500 shares of US Energy at 1.84 subject to Rule 16b-3 | ||
Ryan Smith over a week ago Acquisition by Ryan Smith of 500 shares of US Energy at 2.1 subject to Rule 16b-3 |
Cryomass Technologies Management Efficiency
The company has return on total asset (ROA) of (0.3296) % which means that it has lost $0.3296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1644) %, meaning that it created substantial loss on money invested by shareholders. Cryomass Technologies' management efficiency ratios could be used to measure how well Cryomass Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Barbara Weiland | MERCK Kommanditgesellschaft auf | 49 | |
| Gerhard Schmitz | MERCK Kommanditgesellschaft auf | 60 | |
| Mba BEcon | Avicanna | N/A | |
| Roland Alvarez | Avicanna | N/A | |
| Frantz Devedec | Avicanna | N/A | |
| Carlos Muete | Avicanna | N/A | |
| Harshil Chovatiya | 1CM Inc | N/A | |
| Belen MD | MERCK Kommanditgesellschaft auf | 63 | |
| Matthias Heinzel | MERCK Kommanditgesellschaft auf | 56 | |
| Kamyar Hosseini | 1CM Inc | N/A | |
| Friederike Rotsch | MERCK Kommanditgesellschaft auf | 51 | |
| Caitlin Johnston | Avicanna | N/A | |
| Ivana Maric | Avicanna | N/A | |
| Tanvi Bhandari | 1CM Inc | N/A | |
| Linda Romano | 1CM Inc | N/A | |
| Peter Guenter | MERCK Kommanditgesellschaft auf | 61 | |
| Dirk Toepfer | MERCK Kommanditgesellschaft auf | N/A | |
Management Performance
| Return On Equity | -1.16 | |||
| Return On Asset | -0.33 |
Cryomass Technologies Leadership Team
Elected by the shareholders, the Cryomass Technologies' board of directors comprises two types of representatives: Cryomass Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cryomass. The board's role is to monitor Cryomass Technologies' management team and ensure that shareholders' interests are well served. Cryomass Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cryomass Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, Chief Officer | ||
| Caroline Lenardon, Consultant | ||
| Ryan Smith, Chief Meds | ||
| Christian Noel, CEO Director | ||
| Janice Matthews, Consultant | ||
| Patricia Kovacevic, Corp Counsel | ||
| Stephen Schroeder, Consultant |
Cryomass Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cryomass Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.16 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 42.41 M | |||
| Shares Outstanding | 202.53 M | |||
| Shares Owned By Insiders | 25.92 % | |||
| Price To Book | 4.44 X | |||
| Gross Profit | 37.18 K | |||
| EBITDA | (7.9 M) | |||
| Net Income | (12.86 M) | |||
| Cash And Equivalents | 2.19 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Cryomass OTC Stock
Cryomass Technologies financial ratios help investors to determine whether Cryomass OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cryomass with respect to the benefits of owning Cryomass Technologies security.